Drugs / M2SR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03553940 | Aug 2018 → Aug 2020 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M2SR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03553940 ↗ |
| Known as | H3N2 M2SR | “This clinical trial is designed to assess the safety and immunogenicity of a prime-boost regimen of H3N2 M2SR intranasal influenza vaccine (manufactured by FluGen) followed by...” NCT03553940 ↗ |
| Modality | Vaccine | “monovalent live attenuated influenza H3N2 M2SR vaccine” NCT03553940 ↗ |
| Route | Intranasal | “Administered intranasally as s single dose.” NCT03553940 ↗ |